

15 December 2013 EMA/HMPC/137299/2013 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Rosa gallica* L., *Rosa centifolia* L., *Rosa damascena* Mill., flos

Draft

Discussion in Working Party on Community monographs and Community list (MLWP)	May 2013 July 2013
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	17 September 2013
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu	15 April 2014
Rediscussion in Working Party on Community monographs and Community list (MLWP)	
Adoption by Committee on Herbal Medicinal Products (HMPC)	

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos; Rosae flos;
	Rose flower

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

BG (bulgarski): Маслодайна роза, цвят	LT (lietuvių kalba): Rožių žiedai
CS (čeština): růžový květ	LV (latviešu valoda): Rožu ziedi
DA (dansk): Rosenblomst	MT (Malti): Fjura tal-Ward
DE (Deutsch): Rosenblütenblätter	NL (Nederlands): Roos, bloem
EL (elliniká): Ρόδου ἀνθος	PL (polski): Kwiat róży
EN (English): Rose flower	PT (português): Rosa, flor
ES (español): Rosa, flor de	RO (română):
ET (eesti keel): kibuvitsaõis	SK (slovenčina): Kvet ruže
FI (suomi): ruusu, kukka	SL (slovenščina): cvet vrtnice
FR (français): Rose pâle, rose de Provins, rose de	SV (svenska): Rosenblad
Damas	IS (íslenska):
HR (hrvatski): ružin cvijet	NO (norsk): Roseblomst
HU (magyar): Rózsavirág	
IT (italiano): Rosa fiore	

Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos (Rose flower)
	i) Herbal substance
	Dried petals
	ii) Herbal preparations
	Comminuted herbal substance

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal substance or comminuted herbal substance for infusion preparation for oromucosal or cutaneous use. The pharmaceutical form should be described by full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product used for mild inflammations of the oral and pharyngeal mucosa.

 ¹ The material complies with the monograph in the Ph. Fr. XI edition (Rose pâle 1989; Rose rouge 1989).
² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Well-established use	Traditional use
	Indication 2) Traditional herbal medicinal product used for relief of minor skin inflammation. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration³

Well-established use	Traditional use
	Posology
	Indication 1)
	Adolescents over 12 years of age, adults and elderly
	Single dose
	Herbal substance or comminuted herbal substance for infusion preparation for oromucosal use: 1 – 2 g of the herbal substance or comminuted herbal substance in 200 ml of boiling water
	As a mouth rinse, up to 3 times daily.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Indication 2)
	Adolescents over 12 years of age, adults and elderly
	Single dose
	Herbal substance or comminuted herbal substance for infusion preparation for cutaneous use: 1 – 2 g of the herbal substance or comminuted herbal substance in 200 ml of boiling water
	Apply on the affected area, up to 3 times daily, in the form of a wet, impregnated dressing.
	The use in children under 12 years of age is not

³ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indications 1) and 2)
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oromucosal use. Cutaneous use.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indications 1) and 2)
	The use in children under 12 years of age has not been established due to lack of adequate.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	No fertility data available.
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None reported. If adverse reactions occur, a doctor or a
	qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Traditional use
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on genotoxicity, reproductive toxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

15 December 2013